What are you searching for?

01.09.2021 | Tracker

Product Launch Tracker


Every month CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

The conversation Level of HCPs discussing product launches on Twitter

Throughout August 2021 we tracked the global conversations of 9,265 HCPs who posted 18,563 English-language Twitter posts about the launches and approvals of new products.

The latest product approval insights

In August 2021, the new product approvals that caught HCPs’ attention were Merck & Co subsidiary Peloton Therapeutics’ Welireg (belzutifan) treatment for patients with Von Hippel-Lindau syndrome (VHL), as well as Jardiance (empagliflozin), a Boehringer Ingelheim and Eli Lilly and Company product used to treat adults living with heart failure with reduced ejection fraction. However, the conversation among HCPs around these approvals was overshadowed by the discussion of the FDA’s approval of the Pfizer vaccine for the prevention of COVID-19 disease in all individuals 16 years of age or older – before this point the vaccine had only been granted authorisation for emergency use. This caused the overall volume of HCP tweets discussing product launches in August to be more than three times higher than the previous month.

HCPs such as Emergency medicine physician, Raul Ruiz, and physician, Ashish K. Jha celebrated the news of the Pfizer vaccine gaining full approval. Many also took the opportunity to encourage people to get vaccinated. However, some HCPs felt it would still take several months for this to impact vaccine rates significantly enough to tame the virus.

Alongside HCPs conversations on the approval of the Pfizer vaccine, many HCPs also referenced the lack of FDA approval of Ivermectin as a treatment for COVID-19 – with over 1,000 HCPs sharing the FDAs warning against the use of the drug.

Though the level of HCP engagement around the FDA approvals of Welireg (belzutifan) and Jardiance (empagliflozin) was notably lower than that around the Pfizer vaccine, those that were commenting on the news spoke positively about both drugs. Welireg was heralded as a great step forward for patients with cancers with VHL and HCPs were impressed with Jardiance’s strong trial results.

The three most shared links from HCPs discussing product launches in June were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches. You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development, and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up for CREATION.co’s monthly eJournal.

The Product Launch tracker archive

July 2021:  HCPs celebrate Merck & Co and Bayer approvals while discussing Modernas’s extension at length

June 2021: HCPs optimistic over Novo Nordisk and Roche approvals but still to be won over by Biogen’s aducanumab

View all articles >

Meet the Author


Suggested next

A CREATION Press Release

07.06.2013 | Press Release

Arrhythmia most talked about subject by doctors in new social media study on heart disease

Arrhythmia most talked about subject by doctors in new social media study on heart disease

11.10.2019 | Article

Opdivo and Keytruda share the spotlight at ESMO 2019

Opdivo and Keytruda share the spotlight at ESMO 2019

By Laura McIntyre

View all articles >